目的：探讨Ｄ二聚体（Ｄｄｉｍｅｒ）变化与原发性肝癌临床分期关系。方法：采用酶联免疫吸附反应检测了８５例不同临床分期肝癌患者血浆Ｄ二聚体含量。结果：各临床分期肝癌患者Ｄ二聚体均显著高于对照组（Ｐ＜００１），且不同临床分期肝癌患者之间，Ｄ二聚体含量相差非常显著（Ｐ＜００１）。随肝癌患者病情加重，转移发生，Ｄ二聚体呈递增趋势，在Ⅲ期患者，Ｄ二聚体１００％升高。结论：Ｄ二聚体不仅可以反映患者呈现不同程度的纤溶亢进，而且可以作为肝癌患者预后判断的指标。 Objective: To investigate the relationship between Ddimer changes and the clinical stage of primary liver cancer. Methods: The plasma D-dimer content in 85 patients with different clinical stages of liver cancer was detected by enzyme-linked immunosorbent assay. Results: The Ddimer of liver cancer patients in each clinical stage was significantly higher than that in the control group (P<001), and the difference in Ddimer content between patients with different clinical stages of liver cancer was very significant (P<001). ). With the worsening of liver cancer patients, metastasis occurred, D-dimer increased gradually. In stage III patients, D-dimer increased by 100%. Conclusion: D-dimer can not only reflect the degree of fibrinolysis in patients with different degrees, but also can be used as an indicator of prognosis of liver cancer patients.